Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc (HOLX) delivers innovative healthcare solutions through diagnostic imaging systems and surgical technologies focused on women’s health. This dedicated news hub provides investors and industry professionals with essential updates directly from the company and verified sources.
Access timely Hologic press releases, earnings reports, and strategic announcements in one centralized location. Track developments across key business segments including diagnostic systems, breast health technologies, and minimally invasive surgical solutions. Our curated feed ensures you never miss regulatory filings, product approvals, or partnership announcements impacting this medical technology leader.
This resource serves as your primary source for monitoring Hologic’s advancements in healthcare diagnostics and operational milestones. Content is rigorously verified to maintain factual accuracy while avoiding speculative analysis. Bookmark this page for efficient tracking of HOLX’s progress in developing technologies that enhance clinical decision-making worldwide.
Hologic (HOLX) reported strong Q4 2024 financial results with revenue of $987.9 million, up 4.5% year-over-year. The company achieved GAAP EPS of $0.76 and Non-GAAP EPS of $1.01. Organic revenue excluding COVID-19 grew 5.0% in constant currency. Key segment performance included Diagnostics revenue increasing 6.5%, Breast Health revenue rising 6.4%, and Surgical revenue growing 5.7%. The company maintained strong cash flow from operations at $367.1 million and announced plans for a $250 million accelerated share repurchase program. Hologic completed the acquisition of Endomagnetics for $310 million and announced an agreement to acquire Gynesonics for approximately $350 million.
Hologic, Inc. (Nasdaq: HOLX), a global women's health champion, has announced a definitive agreement to acquire Gynesonics, Inc., a private medical device company, for approximately $350 million. Gynesonics develops the Sonata® System, a minimally invasive technology for diagnosing and treating symptomatic uterine fibroids, including those causing heavy menstrual bleeding. The system combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure.
Brandon Schnittker, Division President of Surgical Solutions at Hologic, stated that the acquisition will expand options for GYN surgeons globally to treat women with heavy periods and fibroids. The deal aligns with Hologic's commitment to providing minimally invasive treatment options and enhancing women's quality of life. The acquisition's completion is subject to customary closing conditions and regulatory approvals.
Hologic (Nasdaq: HOLX) has announced plans to release its financial results for the fourth quarter of fiscal 2024 on Monday, November 4, after market close. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results.
Interested participants can join the call by dialing (888) 394-8218 (US and Canada) or +1 (773) 305-6853 (international) with access code 4567924. A live webcast and replay will be available on Hologic's investor relations website for 30 days. The webcast replay will be accessible approximately two hours after the call ends.
Hologic is an innovative medical technology company primarily focused on improving women's health through early detection and treatment.
Hologic (Nasdaq: HOLX) launches the #BustTheMyth campaign for Breast Cancer Awareness Month, aiming to debunk common misconceptions about breast cancer, mammograms, and breast density. The company will ring the Nasdaq opening bell for the 18th year to kick off this initiative.
The campaign addresses key myths, such as the misconception that only those with a family history need mammograms, when in fact 85% of women diagnosed have no family history. It also emphasizes that breast density, a risk factor for breast cancer, can only be determined by mammograms.
Hologic's effort comes at a important time, following updated breast cancer screening guidelines and new FDA reporting standards on breast density. The company's 3D Mammography™ exam is FDA-approved as superior for women with dense breasts compared to 2D alone.
Despite breast cancer being highly treatable when detected early, over 40% of U.S. women report skipping screenings. Hologic aims to empower women with facts to prioritize their health and encourage annual screenings.
Hologic (Nasdaq: HOLX), a leading medical technology company focused on women's health, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on September 5th at 12:20 p.m. Eastern Time in New York.
The company will engage in a fire-side chat presentation, which will be webcast live and accessible through the investors section of Hologic's website. The webcast will remain available for 30 days following the event, providing an opportunity for investors and interested parties to gain insights into Hologic's latest developments and strategies.
This presentation at a major healthcare conference underscores Hologic's commitment to transparency and engagement with the investment community, potentially impacting investor perceptions and the company's stock performance.
Hologic (NASDAQ: HOLX) reported strong financial results for Q3 fiscal 2024, with revenue of $1,011.4 million, up 2.7% year-over-year. GAAP EPS was $0.82, and non-GAAP EPS was $1.06, both exceeding guidance. Organic revenue excluding COVID-19 grew 5.8% in constant currency. Key highlights include:
- Diagnostics revenue increased 0.3%, with Molecular Diagnostics up 2.8%
- Breast Health revenue rose 6.9%, driven by strong gantry sales and service
- Surgical revenue grew 5.9%
- Cash flow from operations was $405.7 million
- The company repurchased 1.4 million shares for $100 million
Hologic raised its full-year 2024 revenue guidance to $4,012 - $4,027 million and non-GAAP EPS guidance to $4.04 - $4.11. The company's strong performance demonstrates the durability of its broad portfolio across Diagnostics, Breast Health, and Surgical franchises.
Hologic (Nasdaq: HOLX) has completed its acquisition of Endomagnetics (Endomag), a UK-based developer of breast cancer surgery technologies, for approximately $310 million. This acquisition adds Endomag's wireless breast surgery localization and lymphatic tracing solutions to Hologic's breast surgery portfolio, including the Magseed® marker, Magtrace® lymphatic tracer, and Sentimag® platform.
The integration aims to provide breast surgeons and radiologists with an expanded range of options and enhanced user experience. Hologic's President of Breast and Skeletal Health Solutions, Erik Anderson, expressed enthusiasm about increasing access to Endomag's innovative technologies and improving outcomes for patients. Endomag's CEO, Eric Mayes, shared optimism about the opportunities for their team and the potential to impact more women globally.
A recent survey by Hologic reveals a significant gap in health screenings among American women. Despite 90% of women acknowledging the importance of regular screenings, 72 million have skipped or delayed essential tests, such as those for breast, cervical, and colorectal cancers. The Hologic Global Women's Health Index, conducted by Gallup, surveyed 4,001 women and found key barriers including lack of awareness, anxiety, and time constraints. The study highlights the need for increased awareness and education to encourage timely screenings.
Hologic (Nasdaq: HOLX) announced that it will release its financial results for the third quarter of fiscal 2024 on July 29, 2024, after the market closes.
Management will host a conference call at 4:30 p.m. Eastern Time to discuss the results. To participate, dial (888) 394-8218 in the U.S. and Canada, or +1 (773) 305-6853 internationally, using access code 5372869. Alternatively, participants can join the webcast on Hologic's investor relations website.
A live and recorded webcast replay will be available on the website for 30 days, starting about two hours after the call concludes.
Hologic focuses on medical technologies that improve women's health and well-being through early detection and treatment.
Hologic (Nasdaq: HOLX) has announced its participation in two upcoming investor conferences. The company will present at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on May 29th at 10 a.m. CT. Additionally, Hologic will present at the William Blair 44th Annual Growth Stock Conference in Chicago, Illinois on June 4th at 8:40 a.m. CT. Both presentations will be webcast live and available for 30 days on the company’s investor relations website.
